389 related articles for article (PubMed ID: 2997275)
1. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes.
Matzner Y; Bar-Ner M; Yahalom J; Ishai-Michaeli R; Fuks Z; Vlodavsky I
J Clin Invest; 1985 Oct; 76(4):1306-13. PubMed ID: 2997275
[TBL] [Abstract][Full Text] [Related]
2. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
Bar-Ner M; Mayer M; Schirrmacher V; Vlodavsky I
J Cell Physiol; 1986 Aug; 128(2):299-306. PubMed ID: 2426287
[TBL] [Abstract][Full Text] [Related]
3. Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix.
Bashkin P; Razin E; Eldor A; Vlodavsky I
Blood; 1990 Jun; 75(11):2204-12. PubMed ID: 1693299
[TBL] [Abstract][Full Text] [Related]
4. Heparanase activity in cultured endothelial cells.
Godder K; Vlodavsky I; Eldor A; Weksler BB; Haimovitz-Freidman A; Fuks Z
J Cell Physiol; 1991 Aug; 148(2):274-80. PubMed ID: 1880155
[TBL] [Abstract][Full Text] [Related]
5. Subcellular localization of heparanase in human neutrophils.
Matzner Y; Vlodavsky I; Bar-Ner M; Ishai-Michaeli R; Tauber AI
J Leukoc Biol; 1992 Jun; 51(6):519-24. PubMed ID: 1613389
[TBL] [Abstract][Full Text] [Related]
6. Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells.
Bar-Ner M; Kramer MD; Schirrmacher V; Ishai-Michaeli R; Fuks Z; Vlodavsky I
Int J Cancer; 1985 Apr; 35(4):483-91. PubMed ID: 3157649
[TBL] [Abstract][Full Text] [Related]
7. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
8. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.
Vlodavsky I; Eldor A; Haimovitz-Friedman A; Matzner Y; Ishai-Michaeli R; Lider O; Naparstek Y; Cohen IR; Fuks Z
Invasion Metastasis; 1992; 12(2):112-27. PubMed ID: 1399400
[TBL] [Abstract][Full Text] [Related]
9. Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase.
Benezra M; Vlodavsky I; Bar-Shavit R
Exp Cell Res; 1992 Jul; 201(1):208-15. PubMed ID: 1612123
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase.
Bartlett MR; Underwood PA; Parish CR
Immunol Cell Biol; 1995 Apr; 73(2):113-24. PubMed ID: 7797231
[TBL] [Abstract][Full Text] [Related]
11. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
12. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase.
Yahalom J; Eldor A; Fuks Z; Vlodavsky I
J Clin Invest; 1984 Nov; 74(5):1842-9. PubMed ID: 6389600
[TBL] [Abstract][Full Text] [Related]
13. Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate.
Marchetti D; Liu S; Spohn WC; Carson DD
J Biol Chem; 1997 Jun; 272(25):15891-7. PubMed ID: 9188488
[TBL] [Abstract][Full Text] [Related]
14. Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix.
Ishai-Michaeli R; Eldor A; Vlodavsky I
Cell Regul; 1990 Oct; 1(11):833-42. PubMed ID: 2088528
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.
Bar-Ner M; Eldor A; Wasserman L; Matzner Y; Cohen IR; Fuks Z; Vlodavsky I
Blood; 1987 Aug; 70(2):551-7. PubMed ID: 2955820
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of neutrophil activation by the subendothelial extracellular matrix: possible role in protection of the vessel wall during diapedesis.
Matzner Y; Vlodavsky I; Michaeli RI; Eldor A
Exp Cell Res; 1990 Aug; 189(2):233-40. PubMed ID: 2164483
[TBL] [Abstract][Full Text] [Related]
17. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases.
Marchetti D
J Cell Physiol; 1997 Sep; 172(3):334-42. PubMed ID: 9284953
[TBL] [Abstract][Full Text] [Related]
18. An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses infiltration of neutrophils and monocytes into inflamed dorsal air pouches.
Sue M; Higashi N; Shida H; Kogane Y; Nishimura Y; Adachi H; Kolaczkowska E; Kepka M; Nakajima M; Irimura T
Int Immunopharmacol; 2016 Jun; 35():15-21. PubMed ID: 27015605
[TBL] [Abstract][Full Text] [Related]
19. Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix.
Eldor A; Bar-Ner M; Yahalom J; Fuks Z; Vlodavsky I
Semin Thromb Hemost; 1987 Oct; 13(4):475-88. PubMed ID: 3321438
[TBL] [Abstract][Full Text] [Related]
20. Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix.
Yahalom J; Fibach E; Bar-Tana R; Fuks Z; Vlodavsky I
Leuk Res; 1988; 12(9):711-7. PubMed ID: 2973542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
